Alligator Bioscience Future Growth

Future criteria checks 5/6

Alligator Bioscience is forecast to grow earnings and revenue by 51.7% and 55.6% per annum respectively while EPS is expected to grow by 7% per annum.

Key information

51.7%

Earnings growth rate

7.0%

EPS growth rate

Biotechs earnings growth	37.0%
Revenue growth rate	55.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Jun 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:ATORXS - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	85	-162	N/A	-149	1
12/31/2024	367	149	N/A	166	2
12/31/2023	79	-146	N/A	-188	3
3/31/2023	40	-213	-178	-177	N/A
12/31/2022	36	-193	-173	-173	N/A
9/30/2022	21	-177	-163	-162	N/A
6/30/2022	20	-163	-149	-148	N/A
3/31/2022	18	-152	-139	-139	N/A
12/31/2021	13	-142	-127	-127	N/A
9/30/2021	8	-139	-125	-125	N/A
6/30/2021	5	-133	-128	-128	N/A
3/31/2021	6	-133	-127	-127	N/A
12/31/2020	6	-143	-141	-141	N/A
9/30/2020	5	-169	-161	-160	N/A
6/30/2020	9	-194	-187	-185	N/A
3/31/2020	4	-209	-199	-197	N/A
12/31/2019	4	-210	-183	-181	N/A
9/30/2019	30	-181	-174	-172	N/A
6/30/2019	26	-164	-156	-154	N/A
3/31/2019	26	-152	-144	-141	N/A
12/31/2018	27	-150	-112	-104	N/A
9/30/2018	53	-107	-112	-97	N/A
6/30/2018	54	-93	-97	-80	N/A
3/31/2018	55	-86	-89	-71	N/A
12/31/2017	57	-64	-114	-100	N/A
9/30/2017	12	-96	-87	-80	N/A
6/30/2017	15	-77	-80	-76	N/A
3/31/2017	18	-91	-44	-41	N/A
12/31/2016	59	-48	N/A	-38	N/A
9/30/2016	55	-68	N/A	-52	N/A
12/31/2015	292	207	N/A	205	N/A
12/31/2014	1	-77	N/A	-63	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATORXS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: ATORXS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ATORXS is expected to become profitable in the next 3 years.

Revenue vs Market: ATORXS's revenue (55.6% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: ATORXS's revenue (55.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATORXS's Return on Equity is forecast to be high in 3 years time

Alligator Bioscience Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings released: kr0.88 loss per share (vs kr1.58 loss in FY 2021)

High number of new directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies